Candel Therapeutics Inc (CADL)

$13.13 +0.78 (6.32%)
Market Cap 1.00B
Revenue (ttm) 0.00
Net Income (ttm) -38.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.38
Volume 1,339,200
Avg Vol 1,627,682
Day's Range N/A - N/A
Shares Out 76.52M
Stochastic %K 80%
Beta -0.51
Analysts Strong Sell
Price Target $21.00

Company Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic,...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 916 5445
Address:
117 Kendrick Street, Suite 450, Needham, United States
LongLongStock
LongLongStock Aug. 24 at 4:07 PM
$CADL so many kings here. The true king is @Kingjake26. Called this since 4 dollars !
0 · Reply
CO145
CO145 Aug. 24 at 4:01 PM
$CADL volume drying up faster than Lake Mead.
1 · Reply
Kingjake26
Kingjake26 Aug. 24 at 3:53 PM
$CADL These spammer is copying my account. Please report this account. @Stocktwits
0 · Reply
Kingjake026
Kingjake026 Aug. 24 at 3:51 PM
$CADL low volume short attack or MM digging for the shares they can get. Don’t fall for it.
1 · Reply
Drcando
Drcando Aug. 24 at 3:22 PM
$CADL KWYO ‼️‼️ KWYO ‼️‼️ Squeeze is in the background imho 🐂🐂🩺🩺🚀🚀🏦🏦🔜🔜
0 · Reply
SilentRider1
SilentRider1 Aug. 24 at 3:16 PM
$CADL do u suck man ?
0 · Reply
ShortKing8figs
ShortKing8figs Aug. 24 at 3:01 PM
$CADL i can’t wait for it to go back down to pennies where it belong 😂😂 buncha degen gambles
0 · Reply
Musky49
Musky49 Aug. 24 at 2:42 PM
$CADL Biomarker data this week or September?
0 · Reply
Musky49
Musky49 Aug. 24 at 2:35 PM
$CADL Not seeing this on my feed.
2 · Reply
cninc
cninc Aug. 24 at 2:25 PM
$CADL won't be long for these low volume sell off to run their course. Green by noon. Nobody is selling down here.
2 · Reply
Latest News on CADL
Candel Therapeutics price target raised to $12 from $9 at BofA

2026-08-16T13:45:29.000Z - 8 days ago

Candel Therapeutics price target raised to $12 from $9 at BofA

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Aug 13, 2026, 8:05 AM EDT - 11 days ago

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Candel Therapeutics Earnings release: Q2 2026

Aug 13, 2026, 8:00 AM EDT - 11 days ago

Candel Therapeutics Earnings release: Q2 2026

Candel Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 8:00 AM EDT - 11 days ago

Candel Therapeutics Quarterly report: Q2 2026

Candel Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference

Aug 12, 2026, 12:00 PM EDT - 12 days ago

Candel Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 3, 2026, 4:05 PM EDT - 20 days ago

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

Aug 3, 2026, 8:05 AM EDT - 21 days ago

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

Candel Therapeutics to Present at Canaccord Genuity's 46th Annual Growth Conference in Boston

Jul 29, 2026, 8:05 AM EDT - 26 days ago

Candel Therapeutics to Present at Canaccord Genuity's 46th Annual Growth Conference in Boston

Candel Therapeutics initiated with a Buy at Stifel

2026-07-13T09:40:23.000Z - 6 weeks ago

Candel Therapeutics initiated with a Buy at Stifel

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 8, 2026, 4:05 PM EDT - 6 weeks ago

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics Slides: Corporate presentation

Jul 7, 2026, 7:00 AM EDT - 6 weeks ago

Candel Therapeutics Slides: Corporate presentation

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Jun 30, 2026, 8:05 AM EDT - 7 weeks ago

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

Jun 25, 2026, 8:05 AM EDT - 2 months ago

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

Candel Therapeutics Transcript: AGM 2026

Jun 23, 2026, 10:00 AM EDT - 2 months ago

Candel Therapeutics Transcript: AGM 2026

Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 5:30 PM EDT - 2 months ago

Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene

2026-06-02T14:27:23.000Z - 2 months ago

Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Jun 2, 2026, 8:05 AM EDT - 2 months ago

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Candel Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 20, 2026, 10:00 AM EDT - 3 months ago

Candel Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum

Candel Therapeutics price target raised to $9 from $7 at BofA

2026-05-18T19:30:09.000Z - 3 months ago

Candel Therapeutics price target raised to $9 from $7 at BofA

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

May 15, 2026, 4:05 PM EDT - 3 months ago

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

Candel Therapeutics Transcript: Study result

May 15, 2026, 1:00 PM EDT - 3 months ago

Candel Therapeutics Transcript: Study result

Candel Therapeutics Slides: Study result

May 15, 2026, 1:00 PM EDT - 3 months ago

Candel Therapeutics Slides: Study result

Candel Therapeutics Press release: Study result

May 15, 2026, 1:00 PM EDT - 3 months ago

Candel Therapeutics Press release: Study result

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 14, 2026, 8:05 AM EDT - 3 months ago

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Candel Therapeutics Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 3 months ago

Candel Therapeutics Earnings release: Q1 2026

Candel Therapeutics Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 3 months ago

Candel Therapeutics Quarterly report: Q1 2026

Candel Therapeutics Slides: Corporate presentation

May 14, 2026, 7:00 AM EDT - 3 months ago

Candel Therapeutics Slides: Corporate presentation

Candel Therapeutics to Present at Upcoming Investor Conferences

May 13, 2026, 8:05 AM EDT - 3 months ago

Candel Therapeutics to Present at Upcoming Investor Conferences

Candel Therapeutics Slides: Corporate presentation

May 13, 2026, 7:00 AM EDT - 3 months ago

Candel Therapeutics Slides: Corporate presentation

Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

May 4, 2026, 8:05 AM EDT - 4 months ago

Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

Apr 29, 2026, 8:05 AM EDT - 4 months ago

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

Candel Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Candel Therapeutics Proxy statement: Proxy filing

Candel Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Candel Therapeutics Proxy statement: Proxy filing

Candel Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-04-20T10:42:20.000Z - 4 months ago

Candel Therapeutics initiated with an Overweight at Cantor Fitzgerald

Candel Therapeutics Slides: Corporate presentation

Apr 14, 2026, 7:00 AM EDT - 4 months ago

Candel Therapeutics Slides: Corporate presentation

Candel Therapeutics price target raised to $26 from $22 at Citi

2026-03-18T10:22:07.000Z - 5 months ago

Candel Therapeutics price target raised to $26 from $22 at Citi

Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC

2026-03-17T12:22:09.000Z - 5 months ago

Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Mar 17, 2026, 8:05 AM EDT - 5 months ago

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Candel Therapeutics Slides: Corporate presentation

Mar 17, 2026, 7:00 AM EDT - 5 months ago

Candel Therapeutics Slides: Corporate presentation

Candel Therapeutics price target lowered to $22 from $24 at Citi

2026-03-13T10:45:12.000Z - 5 months ago

Candel Therapeutics price target lowered to $22 from $24 at Citi

Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year

2026-03-12T12:11:41.000Z - 5 months ago

Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year

Candel Therapeutics sees cash runway into 1Q28

2026-03-12T12:11:01.000Z - 5 months ago

Candel Therapeutics sees cash runway into 1Q28

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Mar 12, 2026, 8:05 AM EDT - 5 months ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Candel Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 5 months ago

Candel Therapeutics Earnings release: Q4 2025

Candel Therapeutics Annual report: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 5 months ago

Candel Therapeutics Annual report: Q4 2025

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Mar 9, 2026, 8:05 AM EDT - 6 months ago

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Candel Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:50 AM EST - 6 months ago

Candel Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston

Feb 24, 2026, 8:05 AM EST - 6 months ago

Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

2026-02-20T03:25:29.000Z - 6 months ago

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

2026-02-20T03:25:12.000Z - 6 months ago

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

Candel Therapeutics Announces Pricing of Public Offering

Feb 19, 2026, 9:40 PM EST - 6 months ago

Candel Therapeutics Announces Pricing of Public Offering

Candel Therapeutics announces $100M royalty funding agreement

2026-02-19T22:10:17.000Z - 6 months ago

Candel Therapeutics announces $100M royalty funding agreement

Candel Therapeutics announces $100M common stock offering

2026-02-19T21:13:42.000Z - 6 months ago

Candel Therapeutics announces $100M common stock offering

Candel Therapeutics Announces Proposed $100 Million Public Offering

Feb 19, 2026, 4:05 PM EST - 6 months ago

Candel Therapeutics Announces Proposed $100 Million Public Offering

Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Feb 19, 2026, 4:01 PM EST - 6 months ago

Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

Feb 11, 2026, 8:05 AM EST - 6 months ago

Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

Candel Therapeutics Slides: Corporate Presentation

Dec 10, 2025, 7:00 AM EST - 9 months ago

Candel Therapeutics Slides: Corporate Presentation

Candel Therapeutics Transcript: R&D Day 2025

Dec 5, 2025, 11:00 AM EST - 9 months ago

Candel Therapeutics Transcript: R&D Day 2025

Candel Therapeutics Press release: FY 2025

Dec 5, 2025, 11:00 AM EST - 9 months ago

Candel Therapeutics Press release: FY 2025

Candel Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 3:00 AM EST - 9 months ago

Candel Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

Nov 17, 2025, 4:05 PM EST - 9 months ago

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

Candel Therapeutics price target lowered to $24 from $25 at Citi

2025-11-14T11:40:57.000Z - 10 months ago

Candel Therapeutics price target lowered to $24 from $25 at Citi

Candel Therapeutics reports Q3 EPS (21c) vs (33c) last year

2025-11-13T13:31:40.000Z - 10 months ago

Candel Therapeutics reports Q3 EPS (21c) vs (33c) last year

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 13, 2025, 8:25 AM EST - 10 months ago

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

TRIN

Candel Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 10 months ago

Candel Therapeutics Quarterly report: Q3 2025

Candel Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 8:00 AM EST - 10 months ago

Candel Therapeutics Earnings release: Q3 2025

Candel Therapeutics Slides: Corporate Presentation

Nov 12, 2025, 7:00 AM EST - 10 months ago

Candel Therapeutics Slides: Corporate Presentation

Candel Therapeutics announces it will deliver three presentations at SITC

2025-11-04T14:10:59.000Z - 10 months ago

Candel Therapeutics announces it will deliver three presentations at SITC

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Nov 4, 2025, 9:00 AM EST - 10 months ago

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

Nov 3, 2025, 8:05 AM EST - 10 months ago

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

Candel initiated with an Overweight at Stephens on differentiated pipeline

2025-10-28T11:21:24.000Z - 10 months ago

Candel initiated with an Overweight at Stephens on differentiated pipeline

Candel Therapeutics initiated with an Overweight at Stephens

2025-10-27T20:35:14.000Z - 10 months ago

Candel Therapeutics initiated with an Overweight at Stephens

Candel Therapeutics initiated with an Outperform at LifeSci Capital

2025-10-21T10:40:56.000Z - 10 months ago

Candel Therapeutics initiated with an Outperform at LifeSci Capital

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

Oct 16, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

Oct 14, 2025, 8:10 AM EDT - 11 months ago

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

Oct 14, 2025, 8:10 AM EDT - 11 months ago

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

TRIN

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

Oct 14, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Oct 3, 2025, 9:05 AM EDT - 11 months ago

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 29, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 17, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Candel Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 7:00 AM EDT - 1 year ago

Candel Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Candel Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Candel Therapeutics Transcript: Citi's Biopharma Back to School Conference

Sep 3, 2025, 9:00 AM EDT - 1 year ago

Candel Therapeutics Transcript: Citi's Biopharma Back to School Conference

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.

Sep 2, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 28, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 14, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Candel Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Quarterly report: Q2 2025

Candel Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Earnings release: Q2 2025

Candel Therapeutics Registration statement: Registration Filing

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Registration statement: Registration Filing

Candel Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 13, 2025, 2:00 PM EDT - 1 year ago

Candel Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 30, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Jul 24, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

Jul 9, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

Jun 24, 2025, 9:05 AM EDT - 1 year ago

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

Jun 23, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Jun 6, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

May 28, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

May 27, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

May 22, 2025, 5:05 PM EDT - 1 year ago

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Candel Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 7:20 PM EDT - 1 year ago

Candel Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 13, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Candel Therapeutics Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Quarterly report: Q1 2025

Candel Therapeutics Earnings release: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Earnings release: Q1 2025

Candel Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Proxy statement: Proxy Filing

Candel Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Proxy statement: Proxy Filing

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Apr 1, 2025, 8:01 AM EDT - 1 year ago

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D.

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D.

LongLongStock
LongLongStock Aug. 24 at 4:07 PM
$CADL so many kings here. The true king is @Kingjake26. Called this since 4 dollars !
0 · Reply
CO145
CO145 Aug. 24 at 4:01 PM
$CADL volume drying up faster than Lake Mead.
1 · Reply
Kingjake26
Kingjake26 Aug. 24 at 3:53 PM
$CADL These spammer is copying my account. Please report this account. @Stocktwits
0 · Reply
Kingjake026
Kingjake026 Aug. 24 at 3:51 PM
$CADL low volume short attack or MM digging for the shares they can get. Don’t fall for it.
1 · Reply
Drcando
Drcando Aug. 24 at 3:22 PM
$CADL KWYO ‼️‼️ KWYO ‼️‼️ Squeeze is in the background imho 🐂🐂🩺🩺🚀🚀🏦🏦🔜🔜
0 · Reply
SilentRider1
SilentRider1 Aug. 24 at 3:16 PM
$CADL do u suck man ?
0 · Reply
ShortKing8figs
ShortKing8figs Aug. 24 at 3:01 PM
$CADL i can’t wait for it to go back down to pennies where it belong 😂😂 buncha degen gambles
0 · Reply
Musky49
Musky49 Aug. 24 at 2:42 PM
$CADL Biomarker data this week or September?
0 · Reply
Musky49
Musky49 Aug. 24 at 2:35 PM
$CADL Not seeing this on my feed.
2 · Reply
cninc
cninc Aug. 24 at 2:25 PM
$CADL won't be long for these low volume sell off to run their course. Green by noon. Nobody is selling down here.
2 · Reply
oldmanrizzer
oldmanrizzer Aug. 24 at 2:13 PM
$CADL Be like the frog. Don't let those inbred hillbilly MM's take your money.
1 · Reply
OtherOtttawaGuy
OtherOtttawaGuy Aug. 24 at 2:11 PM
$CADL Call the Friday Close. Place your bets until 1600h on Thurs
0 · Reply
Kingjake26
Kingjake26 Aug. 24 at 2:08 PM
$CADL low volume short attack or MM digging for the shares they can get. Don’t fall for it.
0 · Reply
TacomaTRD
TacomaTRD Aug. 24 at 2:02 PM
$CADL SL ? Simply Load...?
0 · Reply
Atomickb
Atomickb Aug. 24 at 2:01 PM
$CADL - low volume manipulation by mm. Will be up in 2 hours
0 · Reply
drizz
drizz Aug. 24 at 2:01 PM
$CADL volume says it all folks / suckas selling this am / smart money loading the dips on our way to mid teens and beyond short term!
0 · Reply
DrHierba
DrHierba Aug. 24 at 1:53 PM
$CADL How is your short from april, arent you enough drawdowned?
2 · Reply
Greyhound9
Greyhound9 Aug. 24 at 1:53 PM
$CADL The person who had a stop loss at 12.50 has lost it now. There are people really knocking on the door, pffffff. 🥵
1 · Reply
Greyhound9
Greyhound9 Aug. 24 at 1:49 PM
$CADL They've really got it together again with a volume of 123K and a 60 cent drop. Well, then it'll probably go up just as fast later. 😉💪🏻
0 · Reply
TacomaTRD
TacomaTRD Aug. 24 at 1:43 PM
$CADL after the dip it'll rip...
1 · Reply
Greyhound9
Greyhound9 Aug. 24 at 1:39 PM
$CADL You can set your clock by it almost every morning. Red, and back up again during the day. 🙏🏻
0 · Reply
chrundel
chrundel Aug. 24 at 1:38 PM
$CADL opening auction seems to favour the bearish side lately... I wouldn't be surprised if we cleared the first hour and things began to coil back up. Selling here doesn't make sense in any case (unless you're a market maker).
1 · Reply